

BIOLASE TECHNOLOGY INC  
Form 8-K  
November 17, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**November 16, 2011**

**Date of Report (Date of earliest event reported)**

**BIOLASE TECHNOLOGY, INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

(State of Incorporation)

(Commission

(IRS Employer

File Number)  
**4 Cromwell**

Identification Number)

**Irvine, California 92618**

(Address of principal executive offices) (Zip Code)

**(949) 361-1200**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On November 16, 2011, Frederick D. Furry, Chief Financial Officer and Chief Operating Officer of Biolase Technology, Inc. (the Company), will deliver a presentation at the Lazard Capital Markets 8th Annual Healthcare Conference that will include a written communication comprised of slides. The slides from the presentation are attached hereto as Exhibit 99.1, and are hereby incorporated by reference.

A copy of the slides will be available for viewing and download at <http://www.biolase.com/investors> for a period of 30 days.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Presentation material from the Lazard Capital Markets 8th Annual Healthcare Conference, dated November 16, 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOLASE TECHNOLOGY, INC.

Date: November 16, 2011

By: /s/ Federico Pignatelli  
Federico Pignatelli  
Chairman and Chief Executive Officer

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Presentation material from the Lazard Capital Markets 8th Annual Healthcare Conference, dated November 16, 2011.